Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors

The Zollinger–Ellison Syndrome and Mismeasurement of Gastrin

(2011) Jens F. Rehfeld et al.   GASTROENTEROLOGY

Chromogranin A and Neuron-Specific Enolase as Prognostic Markers in Patients with Advanced pNET Treated with Everolimus

(2011) James C. Yao et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Elevated Plasma Chromogranin A Is the First Indication of Recurrence in Radically Operated Midgut Carcinoid Tumors

(2009) Staffan Welin et al.   NEUROENDOCRINOLOGY

Plasma Chromogranin A as Marker for Survival in Patients With Metastatic Endocrine Gastroenteropancreatic Tumors

(2008) R ARNOLD et al.   Clinical Gastroenterology and Hepatology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Chromogranin A as an Alternative to 5-Hydroxyindoleacetic Acid in the Evaluation of Symptoms during Treatment of Patients with Neuroendocrine Tumors

(2008) Catharina M. Korse et al.   NEUROENDOCRINOLOGY